옵션 체인은 다양한 행사가격과 만기일에 대한 Kezar Life Sciences의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Kezar Life Sciences에 대한 시장 심리를 평가합니다..

Kezar Life Sciences (NASDAQ:KZR) 주식, 옵션 체인

KEZAR LIFE SCIENCES INC

Kezar Life Sciences

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Kezar Life Sciences Inc

HC Wainwright &amp; Co. analyst Kevin Dede downgrades WonderFi Techs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WNDR#TSX">WNDR</a>) from Buy to Neutral.

News

Downgrades

Analyst Ratings

TSX:WNDR

HC Wainwright & Co. Downgrades WonderFi Techs to Neutral

WIIM

Sanofi share are trading lower after the company announced plans to invest at least $20 billion in the US through 2030.

PONY

Pony AI shares are trading lower. CNBC reported that one of the company's robotaxis caught fire.

Sanofi today announces its intention to invest at least $20 billion in the United States through 2030. The expected investment includes a significant increase in research and development spending and the allocation of billions of dollars to US manufacturing.
The announcement comes as Sanofi prepares for the potential launch of numerous new first- or best-in-class medicines across many indications in the coming years, aiming to improve the health of countless Americans. Work being done within the United States by Sanofi and by the hundreds of companies it supports is anticipated to contribute to job creation and innovation in numerous communities that are home to Sanofi and its partners, while also helping to enhance the US supply chain.

Sanofi Intends To Invest At Least $20B In US Through 2030, Growing Investments In Science And Expanding Domestic Manufacturing

ARAI

Arrive AI Receives Approval To List Its Shares On Nasdaq Under Symbol ARAI; To Begin Trading On May 15, 2025

Needham analyst Ryan Koontz reiterates Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) with a Buy and maintains $8 price target.

Price Target

Reiteration

Needham Reiterates Buy on Planet Labs, Maintains $8 Price Target

V2X Collaborates With Bell Textron To Begin Strategic Planning For U.S. Army's Flight School Next Program

Fidelity National Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) has outperformed the market over the past 5 years by 1.87% on an annualized basis producing an average annual return of 16.9%. Currently, Fidelity National Finl has a market capitalization of $15.60 billion. 
Buying $100 In FNF: If an investor had bought $100 of FNF stock 5 years ago, it would be worth $215.81 today based on a price of $56.79 for FNF at the time of writing.
<h3>Fidelity National Finl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747240311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Fidelity National Finl 5 Years Ago Would Be Worth Today

VRTX

Live On CNBC, Steve Weiss Announces Sold Vertex Pharmaceuticals

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) with a Market Perform and raises the price target from $38 to $40.

NYAX

Keefe, Bruyette & Woods Maintains Market Perform on Nayax, Raises Price Target to $40

Live On CNBC, Steve Weiss Announces Bought More UnitedHealth Group

<a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma#:~:text=On%20May%2014%2C%202025%2C%20the,an%20oral%20therapy%20for%20PPGL" title="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma#:~:text=On%20May%2014%2C%202025%2C%20the,an%20oral%20therapy%20for%20PPGL">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma#:~:text=On%20May%2014%2C%202025%2C%20the,an%20oral%20therapy%20for%20PPGL</a>.

Biotech

General

Reported Earlier: 'FDA Approves Belzutifan For Pheochromocytoma Or Paraganglioma' - FDA

BMO Capital analyst Simeon Siegel maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Outperform and lowers the price target from $12 to $9.

BMO Capital Maintains Outperform on Under Armour, Lowers Price Target to $9

CAE shares are trading lower after the company reported mixed Q4 financial results.

<a href="https://www.bleeckerstreetresearch.com/research/aurora-innovation-aur" title="https://www.bleeckerstreetresearch.com/research/aurora-innovation-aur">https://www.bleeckerstreetresearch.com/research/aurora-innovation-aur</a>

Short Sellers

Watching Aurora Innovation; Bleecker Street Research Issues Report On Co

BMO Capital analyst Simeon Siegel maintains American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) with a Market Perform and lowers the price target from $15 to $11.

BMO Capital Maintains Market Perform on American Eagle Outfitters, Lowers Price Target to $11

BMO Capital analyst Keith Bachman maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Market Perform and raises the price target from $130 to $135.

OKTA

BMO Capital Maintains Market Perform on Okta, Raises Price Target to $135

BMO Capital analyst James Thalacker maintains NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) with a Market Perform and raises the price target from $115 to $167.

BMO Capital Maintains Market Perform on NRG Energy, Raises Price Target to $167

BMO Capital analyst Keith Bachman maintains ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Outperform and raises the price target from $1025 to $1150.

BMO Capital Maintains Outperform on ServiceNow, Raises Price Target to $1150

Millrose Properties shares are trading higher after the company reported Q1 financial results and raised its FY25 guidance for new transaction funding outside of the Lennar Master program.

Press Releases

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

Comments

Kezar Life Sciences

Kezar Life Sciences (KZR) 옵션

Kezar Life Sciences (NASDAQ:KZR) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌